StudyRareStudyRare
Log in to add personal notes on this page.

A child with severe skeletal abnormalities has short trunk, odontoid hypoplasia, and corneal clouding but normal intelligence.

AR; two lysosomal enzymes of keratan sulfate breakdown. Biallelic loss-of-function variants.

  • Type A: GALNS (N-acetylgalactosamine-6-sulfatase)
  • Type B: GLB1 (beta-galactosidase)

Both forms block the lysosomal breakdown of keratan sulfate, and the stored keratan sulfate, mainly in cartilage and its extracellular matrix, bone, and cornea, gives the skeletal dysplasia and corneal clouding. Intelligence is typically normal, and neurologic problems mostly come from the spine, above all odontoid hypoplasia with atlantoaxial instability (90% in type A) that can compress the upper cervical cord.

  • Variants in GALNS (type A): the enzyme removes the O-linked sulfate from keratan sulfate and chondroitin-6-sulfate, so both accumulate. Missense, nonsense, splice, deep intronic, small and large insertions and deletions, and complex rearrangements are all reported; they cause misfolding with early degradation, mislocalization, or a damaged catalytic site. Deletions and nonsense variants, and missense changes in the active site or protein core, go with rapid, severe growth failure; surface missense variants (p.Asp60Asn, p.Arg259Gln) are milder.
  • Variants in GLB1 (type B): the same enzyme degrades GM1 ganglioside. Variants that damage its keratan sulfate binding site (such as p.Trp273Leu) give MPS IVB with little ganglioside storage, while others give GM1 gangliosidosis or a blended picture.
N-acetylgalactosamine-6-sulfatase,and beta-galactosidaseGALNS, GLB1; alsochondroitin-6-sulfate; GLB1 alsodegrades GM1 gangliosideMPS IV, types A (GALNS) and B(GLB1)keratan sulfatekeratan sulfatebroken down
Excerpt from lysosomal glycosaminoglycan degradation. See the full pathway.

Part of lysosomal glycosaminoglycan degradation.

Lysosomal degradation of keratan sulfate, by enzymes that each remove a sugar or a sulfate from the end of the chain.

keratan sulfate (and chondroitin-6-sulfate) → lysosome → N-acetylgalactosamine-6-sulfatase (block in type A) or beta-galactosidase (block in type B) → further stepwise degradation → free sugars and sulfate

  • Accumulates: keratan sulfate, measured in urine (which does not separate type A from type B, and can be falsely normal); the enzyme assay makes the distinction.
  • Missing: the chain's breakdown products; the disease comes from storage in cartilage, bone, and cornea.
  • Workbook: 7.I. Other mucopolysaccharidoses
  • Severe skeletal involvement
  • Normal intelligence
  • Corneal clouding
  • Odontoid hypoplasia (cervical instability)
  • Keratan sulfate elevated
  • Urine glycosaminoglycans: elevated keratan sulfate (urinary GAG can be falsely normal, so a normal screen does not exclude the diagnosis)
  • Deficient enzyme activity: type A (GALNS, N-acetylgalactosamine-6-sulfatase), type B (GLB1, beta-galactosidase)
  • Molecular confirmation of GALNS or GLB1; skeletal survey shows dysostosis multiplex with platyspondyly and odontoid hypoplasia
  • Cervical spine imaging and surveillance for atlantoaxial instability (odontoid hypoplasia); cervical fusion to prevent cord compression
  • Enzyme replacement therapy with elosulfase alfa for type A
  • Multidisciplinary care: orthopedics, pulmonology, cardiology (valve disease), audiology, ophthalmology; avoid contact sports

"Mor-QU-io" = MPS IV: QUad = 4, so MorQUio = MPS IV.

"MorKio has Keratan sulfate": the "K" sound in Morquio links to keratan sulfate (the accumulated substrate).

"Mind is intact in Morquio": no intellectual disability (unlike other MPS types). "Morquio is smart enough to play in an orquestra."

MPS VI is "Stuck" (contractures), MPS IV is Flexible (ligamentous laxity): helps distinguish Morquio (IV) from Maroteaux-Lamy (VI).

Reference Links